Teachers, retirees, recent graduates, and maybe a few people playing hooky. We met the fans making the most of a weekday at the ballpark.
AbbVie today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell engaging bispecific antibody, and lenalidomide, compared to rituximab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results